Artbio, a clinical-stage radiopharmaceutical biotech company, has secured a significant $132 million Series B funding round with the backing of Qatar’s sovereign wealth fund, the Qatar Investment Authority (QIA). This marks QIA’s first investment in Artbio, highlighting the fund’s strategic focus on supporting innovative biotech companies.
The funding round was led by prominent investors including Sofinnova Investments, B Capital, and other key players in the life sciences investment sector. With a strong emphasis on developing alpha radioligand therapies (ARTs) for various cancers, Artbio is at the forefront of cutting-edge biotechnology research. The involvement of QIA underscores the growing interest of sovereign wealth funds in the biotech industry, following QIA’s recent investments in other US-based biotech firms. This strategic partnership is poised to drive further advancements in the field of radiopharmaceuticals and cancer treatment.
Read more on zawya.com